Chief Scientific Officer
CurrentAccountable for scientific activities at Zentalis spanning drug discovery through clinical development
Dec 2023 - Present
AeroLeads people directory · profile
Mark Lackner Email & Phone Number
Chief Scientific Officer at Zentalis
at
Zentalis Pharmaceuticals
2 work emails found
@earthlink.net
6 phones found area 650, 415, 530, and 510
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
Chief Scientific Officer at Zentalis
Location
San Mateo, California, United States
Who is Mark Lackner? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Mark Lackner is listed as Chief Scientific Officer at Zentalis at Zentalis Pharmaceuticals, based in San Mateo, California, United States. AeroLeads shows a work email signal at earthlink.net, phone signal with area code 650, 415, 530, 510, and a matched LinkedIn profile for Mark Lackner.
Mark Lackner previously worked as Chief Scientific Officer at Zentalis Pharmaceuticals and Chief Translational Officer, Head of Biomarker Strategy at Zentalis Pharmaceuticals. Mark Lackner holds Phd, Developmental Biology from Stanford University School Of Medicine.
Company email context
Email format at Zentalis Pharmaceuticals
This section adds company-level context without repeating Mark Lackner's masked contact details.
*@earthlink.net
71% confidence
AeroLeads found 2 current-domain work email signals for Mark Lackner. Compare company email patterns before reaching out.
Profile bio
About Mark Lackner
Experienced drug development scientist and senior manager with over 20 years experience and substantial expertise in oncology drug development ranging from target identification through registrational clinical studies. Strong scientific leader with a passion for drug development and translational medicine.Strong publication record in Oncology with over 60 peer reviewed manuscripts.Specialties: Team leadership, discovery biology, biomarker and diagnostic development, oncology drug development, cancer biology, personalized medicine
Listed skills include Drug Development, Biomarkers, Oncology, Assay Development, and 18 others.
Current workplace
Mark Lackner's current company
Company context helps verify the profile and gives searchers a useful next step.
11 roles
Mark Lackner work experience
A career timeline built from the work history available for this profile.
Chief Translational Officer, Head Of Biomarker Strategy
Oct 2022 - Dec 2023
Jun 2021 - Present
Senior Vice President
Head of Biology and Translational Sciences. Lead Biology team accountable for preclinical target validation, biology support of lead optimization and in vivo pharmacology for projects across the IDEAYA Precision Medicine Pipeline. Lead translational group that is accountable for diagnostic and pharmacodynamic biomarker strategy for our lead clinical asset the PKC inhibitor IDE196, as well as biomarker discovery for earlier stage programs.
Dec 2018 - Oct 2022
May 2018 - Nov 2018
Director & Principal Scientist, Oncology Biomarker Development
- Department Head, Genentech Oncology Early Stage Biomarker Group-Lead a group of 46 researchers developing and incorporating PD and predictive biomarker strategies in phase I and II clinical trials-Responsible for overall biomarker strategies for a diverse portfolio ranging from cancer signaling small molecules to novel immunotherapy agents. Chair of Oncology Biomarker Review forum accountable for biomarker strategies for entire Early Development portfolio-Accountable for overall Genentech breast cancer biomarker strategy-My laboratory has made substantial contributions to the understanding of breast cancer molecular subsets, and also has longstanding interest in the clinical validation of circulating biomarkers such as CTCs and ctDNA in diagnosis and monitoring of cancer-Over 50 peer reviewed publications and review articles with over 3000 cumulative citations
Jun 2015 - May 2018
Associate Director And Senior Scientist, Oncology Biomarker Development
- Department Head, Genentech Oncology Early Stage Biomarker Group-Lead a group of 46 researchers developing and incorporating PD and predictive biomarker strategies in phase I and II clinical trials-Management includes internal clinical biomarker assays group-Accountable for overall Genentech breast cancer biomarker strategy-Member of corporate governance review body accountable for high level decision making
Mar 2012 - Jun 2015
Senior Scientist And Group Leader
-Diagnostic project team leader for five development phase programs-Responsible for development and implemenation of clinical diagnostic strategy -Group leader with seven direct reports, including 3 Ph.D.'s-First and last author publications in high impact cancer journals including Cancer Cell, Cancer Research and Clinical Cancer Research-Expertise leading experimental programs aimed at discovery of novel predictive biomarkers for oncology programs using pharmacogenomics -Development of clinical diagnostic assays (eg qRT-PCR, mutation detection) that work in formalin fixed paraffin embedded tissue-Development and implementation of novel diagnostic platforms, including molecular characterization of circulating tumor cells and proteomics.
Aug 2009 - Mar 2012
Scientist
-Diagnostic project team leader for five development phase programs-Responsible for development and implemenation of clinical diagnostic strategy -Group leader with six direct reports, including 2 Ph.D.'s
Nov 2004 - Aug 2009
Research Scientist
-Project leader, oncology target discovery -Supervised a group of three scientists identifying therapeutic targets in the p53 pathwayPublished work:Lackner et al "Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors."Cancer Cell. 2005 7(4):325-36.
Nov 1999 - Jul 2004
Postdoctoral Researcher
Genetic analysis of serotonin signaling in C. elegans in the laboratory of Josh Kaplan.
Sep 1997 - Oct 1999
3 education records
Mark Lackner education
Phd, Developmental Biology
Stanford University School Of Medicine
Postdoctoral Fellow, Molecular Genetics
University Of California, Berkeley
Bs, Ms, Biology Honors
University Of Illinois Urbana-Champaign
FAQ
Frequently asked questions about Mark Lackner
Quick answers generated from the profile data available on this page.
What company does Mark Lackner work for?
Mark Lackner works for Zentalis Pharmaceuticals.
What is Mark Lackner's role at Zentalis Pharmaceuticals?
Mark Lackner is listed as Chief Scientific Officer at Zentalis at Zentalis Pharmaceuticals.
What is Mark Lackner's email address?
AeroLeads has found 2 work email signals at @earthlink.net for Mark Lackner at Zentalis Pharmaceuticals.
What is Mark Lackner's phone number?
AeroLeads has found 6 phone signal(s) with area code 650, 415, 530, 510 for Mark Lackner at Zentalis Pharmaceuticals.
Where is Mark Lackner based?
Mark Lackner is based in San Mateo, California, United States while working with Zentalis Pharmaceuticals.
What companies has Mark Lackner worked for?
Mark Lackner has worked for Zentalis Pharmaceuticals, Onc.Ai, Ideaya Biosciences, Genentech, and Exelixis.
How can I contact Mark Lackner?
You can use AeroLeads to view verified contact signals for Mark Lackner at Zentalis Pharmaceuticals, including work email, phone, and LinkedIn data when available.
What schools did Mark Lackner attend?
Mark Lackner holds Phd, Developmental Biology from Stanford University School Of Medicine.
What skills is Mark Lackner known for?
Mark Lackner is listed with skills including Drug Development, Biomarkers, Oncology, Assay Development, Biotechnology, Molecular Biology, Personalized Medicine, and Drug Discovery.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial